(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(2.16%) $83.11
(1.98%) $1.752
(1.50%) $2 245.90
(1.28%) $25.07
(1.49%) $923.25
(0.39%) $0.927
(0.82%) $10.86
(0.13%) $0.792
(0.15%) $92.58
Live Chart Being Loaded With Signals
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia...
Stats | |
---|---|
Today's Volume | 13.71M |
Average Volume | 9.62M |
Market Cap | 10.27B |
EPS | HKD0 ( 2023-08-29 ) |
Last Dividend | HKD0.0600 ( 2020-06-29 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 19.50 |
ATR14 | HKD0.00600 (0.22%) |
Volume Correlation
Luye Pharma Group Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Luye Pharma Group Ltd Correlation - Currency/Commodity
Luye Pharma Group Ltd Financials
Annual | 2022 |
Revenue: | HKD5.98B |
Gross Profit: | HKD4.14B (69.22 %) |
EPS: | HKD0.170 |
Q2 | 2023 |
Revenue: | HKD1.45B |
Gross Profit: | HKD971.68M (66.92 %) |
EPS: | HKD0.0203 |
Q1 | 2023 |
Revenue: | HKD1.45B |
Gross Profit: | HKD971.68M (66.92 %) |
EPS: | HKD0.0203 |
Q4 | 2022 |
Revenue: | HKD1.57B |
Gross Profit: | HKD1.05B (66.77 %) |
EPS: | HKD0.0442 |
Financial Reports:
No articles found.
Luye Pharma Group Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0370 | 2016-10-04 |
Last Dividend | HKD0.0600 | 2020-06-29 |
Next Dividend | HKD0 | N/A |
Payout Date | 2020-07-24 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.406 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.71 | -- |
Div. Sustainability Score | 7.51 | |
Div.Growth Potential Score | 3.34 | |
Div. Directional Score | 5.42 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8473.HK | Ex Dividend Knight | 2023-08-15 | Annually | 0 | 0.00% | |
2099.HK | Ex Dividend Junior | 2023-04-19 | Annually | 0 | 0.00% | |
1117.HK | Ex Dividend Junior | 2023-06-08 | Sporadic | 0 | 0.00% | |
0217.HK | Ex Dividend Junior | 2023-07-05 | Sporadic | 0 | 0.00% | |
3788.HK | Ex Dividend Junior | 2023-10-05 | Annually | 0 | 0.00% | |
1696.HK | Ex Dividend Junior | 2023-08-24 | Annually | 0 | 0.00% | |
0743.HK | Ex Dividend Knight | 2023-07-07 | Annually | 0 | 0.00% | |
2238.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1271.HK | Ex Dividend Junior | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
0336.HK | Ex Dividend Junior | 2023-09-13 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0759 | 1.500 | 8.48 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0174 | 1.200 | 9.42 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0426 | 1.500 | -0.638 | -0.957 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.149 | 0.800 | 9.25 | 7.40 | [1 - 3] |
quickRatioTTM | 0.885 | 0.800 | 9.50 | 7.60 | [0.8 - 2.5] |
cashRatioTTM | 0.392 | 1.500 | 8.93 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.375 | -1.500 | 3.75 | -5.62 | [0 - 0.6] |
interestCoverageTTM | 0.863 | 1.000 | -0.791 | -0.791 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.471 | 2.00 | 9.84 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.146 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.871 | -1.500 | 6.52 | -9.78 | [0 - 2.5] |
grossProfitMarginTTM | 0.668 | 1.000 | 2.19 | 2.19 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0910 | 1.000 | -0.180 | -0.180 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.176 | 1.000 | -0.132 | -0.132 | [0.2 - 2] |
assetTurnoverTTM | 0.229 | 0.800 | -1.804 | -1.443 | [0.5 - 2] |
Total Score | 7.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.93 | 1.000 | 7.99 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0426 | 2.50 | -0.410 | -0.957 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.146 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.471 | 2.00 | 9.84 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.890 | 1.500 | 0.734 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.288 | 1.000 | 5.30 | 0 | [0.1 - 0.5] |
Total Score | 3.34 |
Luye Pharma Group Ltd
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators